Vaxart, Inc. (VXRT) stock
VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.48+0.02 (+5.04%)
Close on Oct 19, 2026Market cap $115.15MP/E 3.2Yield –
Vaxart free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Vaxart's free cash flow for the twelve months ending Jun 30, 2026 was $33.38M. For fiscal 2025 it was $7.57M. The highest annual figure on record is $7.57M in fiscal 2025.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.57M | – |
| FY2024 | Dec 31, 2024 | -$45.32M | – |
| FY2023 | Dec 31, 2023 | -$72.32M | – |
| FY2022 | Dec 31, 2022 | -$104.38M | – |
| FY2021 | Dec 31, 2021 | -$64.99M | – |
| FY2020 | Dec 31, 2020 | -$24.97M | – |
| FY2019 | Dec 31, 2019 | -$13.94M | – |
| FY2018 | Dec 31, 2018 | -$15.26M | – |
| FY2016 | Jun 30, 2016 | -$14.30M | – |
| FY2015 | Jun 30, 2015 | -$9.70M | – |
| FY2014 | Jun 30, 2014 | -$3.40M | – |
| FY2013 | Jun 30, 2013 | -$14.90M | – |
| FY2012 | Jun 30, 2012 | -$17.20M | -376.8% |
| FY2009 | Dec 26, 2009 | $6.21M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $2.74M | – |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -$2.50M | – |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $30.66M | – |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $2.48M | – |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -$15.84M | – |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$9.73M | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$7.39M | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$4.21M | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -$12.40M | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$21.32M | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$13.42M | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$15.28M | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$17.93M | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$25.70M | – |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -$33.05M | – |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -$16.64M | – |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -$28.23M | – |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -$26.46M | – |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | -$16.83M | – |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | -$15.59M | – |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | -$15.36M | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -$17.21M | – |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | -$11.67M | – |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | -$9.56M | – |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -$530.00K | – |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | -$3.21M | – |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | -$3.80M | – |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | -$4.46M | – |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | -$476.00K | -106.9% |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | -$5.21M | – |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | -$5.90M | -689.7% |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | -$5.53M | -2865.5% |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | $6.90M | – |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | -$10.73M | – |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | $1.00M | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | $200.00K | – |
See a number that looks wrong?